These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 32514689)

  • 1. The potential of drug repositioning as a short-term strategy for the control and treatment of COVID-19 (SARS-CoV-2): a systematic review.
    Lima WG; Brito JCM; Overhage J; Nizer WSDC
    Arch Virol; 2020 Aug; 165(8):1729-1737. PubMed ID: 32514689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune Modulation as a Therapeutic Option During the SARS-CoV-2 Outbreak: The Case for Antimalarial Aminoquinolines.
    Vitte J; Michel M; Mezouar S; Diallo AB; Boumaza A; Mege JL; Desnues B
    Front Immunol; 2020; 11():2159. PubMed ID: 32983179
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Sachdeva C; Wadhwa A; Kumari A; Hussain F; Jha P; Kaushik NK
    OMICS; 2020 Oct; 24(10):568-580. PubMed ID: 32757981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COVID-19 research: an opinion piece.
    Waters L; Rockstroh JK
    HIV Med; 2020 Sep; 21(8):536-540. PubMed ID: 32544304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Research progress on repositioning drugs and specific therapeutic drugs for SARS-CoV-2.
    Fan S; Xiao D; Wang Y; Liu L; Zhou X; Zhong W
    Future Med Chem; 2020 Sep; 12(17):1565-1578. PubMed ID: 32638628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis.
    Liu W; Zhou P; Chen K; Ye Z; Liu F; Li X; He N; Wu Z; Zhang Q; Gong X; Tang Q; Du X; Ying Y; Xu X; Zhang Y; Liu J; Li Y; Shen N; Couban RJ; Ibrahim QI; Guyatt G; Zhai S
    CMAJ; 2020 Jul; 192(27):E734-E744. PubMed ID: 32493740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro evaluation of antiviral activity of single and combined repurposable drugs against SARS-CoV-2.
    Pizzorno A; Padey B; Dubois J; Julien T; Traversier A; Dulière V; Brun P; Lina B; Rosa-Calatrava M; Terrier O
    Antiviral Res; 2020 Sep; 181():104878. PubMed ID: 32679055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
    Uzunova K; Filipova E; Pavlova V; Vekov T
    Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approaching coronavirus disease 2019: Mechanisms of action of repurposed drugs with potential activity against SARS-CoV-2.
    Lisi L; Lacal PM; Barbaccia ML; Graziani G
    Biochem Pharmacol; 2020 Oct; 180():114169. PubMed ID: 32710969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-SARS-CoV-2 Potential of Artemisinins In Vitro.
    Cao R; Hu H; Li Y; Wang X; Xu M; Liu J; Zhang H; Yan Y; Zhao L; Li W; Zhang T; Xiao D; Guo X; Li Y; Yang J; Hu Z; Wang M; Zhong W
    ACS Infect Dis; 2020 Sep; 6(9):2524-2531. PubMed ID: 32786284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
    Giovane RA; Rezai S; Cleland E; Henderson CE
    Rev Med Virol; 2020 Sep; 30(5):e2136. PubMed ID: 32644275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.
    Aljabali AAA; Bakshi HA; Satija S; Metha M; Prasher P; Ennab RM; Chellappan DK; Gupta G; Negi P; Goyal R; Sharma A; Mishra V; Dureja H; Dua K; Tambuwala MM
    Pharm Nanotechnol; 2020; 8(4):323-353. PubMed ID: 32811406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.
    Li Z; Li X; Huang YY; Wu Y; Liu R; Zhou L; Lin Y; Wu D; Zhang L; Liu H; Xu X; Yu K; Zhang Y; Cui J; Zhan CG; Wang X; Luo HB
    Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27381-27387. PubMed ID: 33051297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.
    Yuan S; Chan JFW; Chik KKH; Chan CCY; Tsang JOL; Liang R; Cao J; Tang K; Chen LL; Wen K; Cai JP; Ye ZW; Lu G; Chu H; Jin DY; Yuen KY
    Pharmacol Res; 2020 Sep; 159():104960. PubMed ID: 32473310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chloroquine for COVID-19: rationale, facts, hopes.
    Cortegiani A; Ippolito M; Ingoglia G; Einav S
    Crit Care; 2020 May; 24(1):210. PubMed ID: 32384908
    [No Abstract]   [Full Text] [Related]  

  • 16. Why Are Lopinavir and Ritonavir Effective against the Newly Emerged Coronavirus 2019? Atomistic Insights into the Inhibitory Mechanisms.
    Nutho B; Mahalapbutr P; Hengphasatporn K; Pattaranggoon NC; Simanon N; Shigeta Y; Hannongbua S; Rungrotmongkol T
    Biochemistry; 2020 May; 59(18):1769-1779. PubMed ID: 32293875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential.
    Xu J; Shi PY; Li H; Zhou J
    ACS Infect Dis; 2020 May; 6(5):909-915. PubMed ID: 32125140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients.
    Liu T; Luo S; Libby P; Shi GP
    Pharmacol Ther; 2020 Sep; 213():107587. PubMed ID: 32470470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SARS-CoV-2: Recent Reports on Antiviral Therapies Based on Lopinavir/Ritonavir, Darunavir/Umifenovir, Hydroxychloroquine, Remdesivir, Favipiravir and other Drugs for the Treatment of the New Coronavirus.
    Costanzo M; De Giglio MAR; Roviello GN
    Curr Med Chem; 2020; 27(27):4536-4541. PubMed ID: 32297571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current Perspective of Antiviral Strategies against COVID-19.
    Ahidjo BA; Loe MWC; Ng YL; Mok CK; Chu JJH
    ACS Infect Dis; 2020 Jul; 6(7):1624-1634. PubMed ID: 32485102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.